Interventional psychiatry

References

• Williams NR, Taylor JJ, Kerns S, et al. Interventional psychiatry: why now? J Clin Psychiatry. 2014;75(8):895–897.
   PubMed Web of Science ®Google Scholar
• Williams NR, Taylor JJ, Snipes JM, et al. Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training? Acad Psychiatry. 2014;38(2):168–176.
   PubMed Web of Science ®Google Scholar
• Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, reliability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–140.
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Lofwall MR, Kim S, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316(3):282–290.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80(6):424–431.
   PubMed Web of Science ®Google Scholar
• Kanes S, Colquhoun H, Gundez-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomized controlled trial. Lancet. 2017;390(10093):480–489.
   PubMed Web of Science ®Google Scholar
• Luedecke D, Schöttle D, Karow A, et al. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015;29(1):41–46.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148.
   PubMed Web of Science ®Google Scholar
• Hollingsworth K, Toscani M. Risk evaluation mitigation strategies: the evolution of risk management policy. Popul Health Manage. 2013;16(2):132–137.
   PubMed Web of Science ®Google Scholar
• Dong B, Chen Z, Yin X, et al. The Efficacy of acupuncture for treating depression-related insomnia compared with a control group: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:9614810.
   PubMed Web of Science ®Google Scholar
• Magid M, Finzi E, Kruger THC, et al. Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry. 2015;48(6):205–210.
   PubMed Web of Science ®Google Scholar
• Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780–787.
   PubMed Web of Science ®Google Scholar
• Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression. Neurotherapeutics. 2017;14:716–727.
   PubMed Web of Science ®Google Scholar
• Iwabuchi SJ, Auer DP, Lankappa ST, et al. Baseline effective connectivity predicts response to repetitive transcranial magnetic stimulation in patients with treatment-resistant depression. Eur Neuropsychopharmacol. 2019;29(5):681–690.
   PubMed Web of Science ®Google Scholar
• Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression. Am J Psychiatry. 2012;169(12):1238–1244.
   PubMed Web of Science ®Google Scholar
• Alonso P, Cuadras D, Gabriëls L, et al. Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response. PLoS One. 2015;10(7):e0133591.
   PubMed Web of Science ®Google Scholar
• Fayek M, Flowers C, Signorelli D. et al. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiat Serv. 2003;54(11):1453–1454, 1456.
   PubMed Web of Science ®Google Scholar
• A call for psychiatrists with clozapine expertise in schizophrenia. Curr Psychiatry. 2017 Sep [cited 2020 Jan 11]. https://www.mdedge.com/psychiatry/article/147076/schizophrenia-other-psychotic-disorders/call-psychiatrists-clozapine
   PubMedGoogle Scholar
• Curry B, Palmer E, Mounce C, et al. Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy. Internet. Ment Health Clin. 2018;8(2):63–67.
   PubMedGoogle Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–484.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• Olfson M. The rise of primary care physicians in the provision of US mental health care. J Health Polit Policy Law. 2016;41(4):559–583.
   PubMed Web of Science ®Google Scholar
• Cocohoba J, Pohlman B, Sang Tran J, et al. Modeling specialty medicine access: understanding key health system process and players. J Am Pharm Assoc. 2019;59(1):43–50.
   Google Scholar
• ACGME. ACGME program requirements for graduate medical education in psychiatry. [cited 2019 Dec 31]. https://www.acgme.org/Portals/0/PFAssets/ProgramRequirements/400_Psychiatry_2019.pdf?ver=2019-08-26-134127-827
   Google Scholar
• Dinwiddie SH, Spitz D. Resident education in electroconvulsive therapy. J Ect. 2010;26(4):310–316.
   PubMed Web of Science ®Google Scholar
• Brown JC. An interventional psychiatry track. Am J Psychiatry Resid J. 2019;15:11–14. [ Epub].
   PubMedGoogle Scholar
• Gishen K, Ovadia S, Arzillo S, et al. The current format and ongoing advances of medical education in the United States. J Craniofac Surg. 2014;25(1):35–38.
   PubMed Web of Science ®Google Scholar
• Butler DJ, Brocato J, Yeazel M. Family medicine didactics revisited. Fam Med. 2017;49(10):778–784.
   PubMed Web of Science ®Google Scholar